Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

Phase 4 Completed 30 enrolled Ingrid Pabinger, MD GlaxoSmithKline · collab

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This is a single-center, prospective, controlled study with one eltrombopag treatment group and 2 control groups, one on standard steroid treatment, and another one untreated. The aim of the study is to determine the effect of Thrombopoietin Receptor (MPL) agonists on shear-induced platelet activation.

Timeline

Start: 2009-05
Primary completion: 2011-03
Completion: 2011-05

Publications

Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost. 2013 Apr;109(4):676-83. doi: 10.1160/TH12-07-0522. Epub 2013 Feb 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eltrombopag	Small molecule	50 mg	Oral
Subject	Eltrombopag	Small molecule	75 mg	Oral
Comparator	Prednisolone	Other / unclassified	1 mg/kg	—

Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With Eltrombopag

Summary

Timeline

Publications

Drugs

Indications